Incorporating cytologic adequacy assessment into precision oncology workflow using telepathology: An institutional experience.
mutational analysis
next-generation sequencing (NGS)
solid tumors
telepathology
Journal
Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
25
03
2021
received:
21
02
2021
accepted:
05
04
2021
pubmed:
1
5
2021
medline:
19
4
2022
entrez:
30
4
2021
Statut:
ppublish
Résumé
Tumor sample quality and quantity determine the success of somatic mutation analysis. Thus, a rapid on-site evaluation (ROSE) tumor cytology adequacy assessment was incorporated into the workflow of precision oncology at Weill Cornell Medicine in New York City. Optimal samples were obtained from 68 patients with metastatic cancer. Cytopathologists performed ROSE on fine-needle aspirate samples via telepathology, and subsequently core-needle biopsies were obtained. In a retrospective manner, the concordance between adequacy assessment and the success rate of the procedure was evaluated to obtain sufficient tumor tissue for next-generation sequencing (NGS). Out of the 68 procedures, 43 were documented as adequate and 25 were documented as inadequate. The diagnostic yield of adequate procedures was 100%. Adequacy evaluation predicted the success rate of molecular profiling in 40 of 43 procedures (93%; 95% CI, 80.9-98.5 procedures). The success rate of molecular testing was significantly higher in the adequate group: 93% compared with 32% in the inadequate group (P < .0005). Seven procedures that failed to provide quality material for mutational analysis and pathological diagnosis were evaluated as inadequate. Cell block provided sufficient DNA for NGS in 6 cases. In 2 cases, a core biopsy could not be performed; hence, the fine-needle aspirate material confirmed the diagnosis and was used for NGS testing. These results support the incorporation of ROSE into the workflow of precision oncology to obtain high-quality tissue samples from metastatic lesions. In addition, NGS testing of concurrent cytology specimens with adequate cellularity can be a surrogate for NGS testing of biopsy specimens.
Sections du résumé
BACKGROUND
Tumor sample quality and quantity determine the success of somatic mutation analysis. Thus, a rapid on-site evaluation (ROSE) tumor cytology adequacy assessment was incorporated into the workflow of precision oncology at Weill Cornell Medicine in New York City. Optimal samples were obtained from 68 patients with metastatic cancer.
METHODS
Cytopathologists performed ROSE on fine-needle aspirate samples via telepathology, and subsequently core-needle biopsies were obtained. In a retrospective manner, the concordance between adequacy assessment and the success rate of the procedure was evaluated to obtain sufficient tumor tissue for next-generation sequencing (NGS).
RESULTS
Out of the 68 procedures, 43 were documented as adequate and 25 were documented as inadequate. The diagnostic yield of adequate procedures was 100%. Adequacy evaluation predicted the success rate of molecular profiling in 40 of 43 procedures (93%; 95% CI, 80.9-98.5 procedures). The success rate of molecular testing was significantly higher in the adequate group: 93% compared with 32% in the inadequate group (P < .0005). Seven procedures that failed to provide quality material for mutational analysis and pathological diagnosis were evaluated as inadequate. Cell block provided sufficient DNA for NGS in 6 cases. In 2 cases, a core biopsy could not be performed; hence, the fine-needle aspirate material confirmed the diagnosis and was used for NGS testing.
CONCLUSION
These results support the incorporation of ROSE into the workflow of precision oncology to obtain high-quality tissue samples from metastatic lesions. In addition, NGS testing of concurrent cytology specimens with adequate cellularity can be a surrogate for NGS testing of biopsy specimens.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
874-883Subventions
Organisme : Caryl and Israel Englander Institute for Precision Medicine
Organisme : Department of Pathology and Laboratory Medicine at Weill Cornell Medicine
Informations de copyright
© 2021 American Cancer Society.
Références
El-Deiry WS, Goldberg RM, Lenz HJ, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019;69:305-343.
Brown NA, Elenitoba-Johnson KSJ. Enabling precision oncology through precision diagnostics. Annu Rev Pathol. 2020;15:97-121.
LeBlanc VG, Marra MA. Next-generation sequencing approaches in cancer: where have they brought us and where will they take us? Cancers (Basel). 2015;7:1925-1958.
Sehn JK, Hagemann IS, Pfeifer JD, Cottrell CE, Lockwood CM. Diagnostic utility of targeted next-generation sequencing in problematic cases. Am J Surg Pathol. 2014;38:534-541.
Pritchard CC, Salipante SJ, Koehler K, et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn. 2014;16:56-67.
Dudley J, Tseng LH, Rooper L, et al. Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers. Arch Pathol Lab Med. 2015;139:211-218.
Al-Kateb H, Nguyen TT, Steger-May K, Pfeifer JD. Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). Mol Oncol. 2015;9:1737-1743.
Sailer V, Schiffman MH, Kossai M, et al. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2018;124:1008-1015.
Morris SM, Subramanian J, Gel ES, et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS One. 2018;13:e0196556.
Ascierto PA, Bifulco C, Palmieri G, Peters S, Sidiropoulos N. Preanalytic variables and tissue stewardship for reliable next-generation sequencing (NGS) clinical analysis. J Mol Diagn. 2019;21:756-767.
VanderLaan PA. Molecular markers: implications for cytopathology and specimen collection. Cancer Cytopathol. 2015;123:454-460.
da Cunha Santos G, Ko HM, Saieg MA, Geddie WR. "The petals and thorns" of ROSE (rapid on-site evaluation). Cancer Cytopathol. 2013;121:4-8.
Ravaioli S, Bravaccini S, Tumedei MM, Pironi F, Candoli P, Puccetti M. Easily detectable cytomorphological features to evaluate during ROSE for rapid lung cancer diagnosis: from cytology to histology. Oncotarget. 2017;8:11199-11205.
Collins BT, Murad FM, Wang JF, Bernadt CT. Rapid on-site evaluation for endoscopic ultrasound-guided fine-needle biopsy of the pancreas decreases the incidence of repeat biopsy procedures. Cancer Cytopathol. 2013;121:518-524.
Kraft AO. Specimen acquisition: ROSEs, gardeners, and gatekeepers. Cancer Cytopathol. 2017;125(suppl 6):449-454.
Lin O. Telecytology for rapid on-site evaluation: current status. J Am Soc Cytopathol. 2018;7:1-6.
Lin DM, Tracht J, Rosenblum F, et al. Rapid on-site evaluation with telecytology significantly reduced unsatisfactory rates of thyroid fine-needle aspiration. Am J Clin Pathol. 2020;153:342-345.
Park K, Tran H, Eng KW, et al. Performance characteristics of a targeted sequencing platform for simultaneous detection of single nucleotide variants, insertions/deletions, copy number alterations, and gene fusions in cancer genome. Arch Pathol Lab Med. 2020;144:1535-1546.
Sailer V, Eng KW, Zhang T, et al. Integrative molecular analysis of patients with advanced and metastatic cancer. JCO Precis Oncol. 2019;3:PO.19.00047.
Rennert H, Eng K, Zhang T, et al. Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. NPJ Genom Med. 2016;1:16019.
Mahajan A, Selvaggi S, Pantanowitz L. Psychological aspects of utilizing telecytology for rapid on-site adequacy assessments. J Pathol Inform. 2018;9:12.
Lin O, Rudomina D, Feratovic R, Sirintrapun SJ. Rapid on-site evaluation using telecytology: a major cancer center experience. Diagn Cytopathol. 2019;47:15-19.
Kaya C, Dorsaint P, Mercurio S, et al. Limitations of detecting genetic variants from the RNA-Seq data in tissue and FNA samples. Thyroid. Published online September 18, 2020. doi:10.1089/thy.2020.0307
Fulmer CG, Park K, Dilcher T, et al. Next-generation sequencing of residual cytologic fixative preserved DNA from pancreatic lesions: a pilot study. Cancer Cytopathol. 2020;128:840-851.